About: Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Creator	Hong, Zhongsi Xia, Jinyu Zeng, Qi Deng, Lisi Li, Chunna Li, Xinghua Liu, Xi Zhang, Haitang
Source	Elsevier; Medline; PMC
abstract	Summary Background Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only. Methods In this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5–21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7). Results We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients’ nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0·05). Conclusion In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.
has issue date	2020-03-11(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2020.03.002
bibo:pmid	32171872
has license	els-covid
sha1sum (hex)	844fe2bd77662e149cfb3564d01aadb04cbd28e5
schema:url	https://doi.org/10.1016/j.jinf.2020.03.002
resource representing a document's title	Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
has PubMed Central identifier	PMC7156152
has PubMed identifier	32171872
schema:publication	J Infect
resource representing a document's body	covid:844fe2bd77662e149cfb3564d01aadb04cbd28e5#body_text
is schema:about of	named entity 'oral' named entity 'pneumonia' named entity 'arbidol' named entity 'LPV' named entity 'patients' named entity 'laboratory' named entity 'NEGATIVE' named entity 'RECEIVED' named entity 'DAYS' named entity 'GROUP' named entity 'DETECTED' named entity 'RESULTS' named entity '2019' named entity 'RETROSPECTIVE COHORT STUDY' named entity 'CHINA' named entity 'MONOTHERAPY' named entity 'CHARACTERISTICS' named entity 'DUE TO' named entity 'SPREAD' named entity 'WAS A' named entity 'CORONAVIRUS' named entity 'FEB' named entity 'CLINICAL' named entity 'DATE' named entity 'CITY' named entity 'GIVEN' named entity 'ORAL' named entity 'TO COMPARE' named entity 'TREATMENT' named entity 'ADULTS' named entity 'ASSESSED' named entity 'RATE' named entity 'COVID-19' named entity 'INVASIVE VENTILATION' named entity 'ANALYZED' named entity 'FAVORABLE' named entity 'PROGRESSING' named entity 'LPV' named entity 'BACKGROUND' named entity 'GROUPS' named entity 'SIMILAR' named entity 'PRIMARY ENDPOINT' named entity 'CLINICAL RESPONSE' named entity 'LOPINAVIR' named entity 'CHEST CT SCANS' named entity 'PNEUMONIA' named entity 'SARS-COV-2' named entity 'CONCLUSION' named entity '2019 NOVEL CORONAVIRUS' named entity 'INCLUDED' named entity 'COMPARED' named entity 'DIAGNOSED' named entity 'SEVEN' named entity 'JAN' named entity 'RAPIDLY' named entity 'CORONA' named entity 'CHEST CT' named entity 'ARBIDOL' named entity 'IMPROVING' named entity 'PATIENTS' named entity 'COMBINATION' named entity 'B79' named entity 'APPARENT' named entity 'BASELINE' named entity 'SPECIMENS' named entity 'CONVERSION' named entity 'WUHAN' named entity 'NASOPHARYNGEAL' named entity 'VIRUS DISEASE' named entity 'METHODS' named entity 'CONFIRMED' named entity 'LABORATORY' covid:arg/844fe2bd77662e149cfb3564d01aadb04cbd28e5 named entity 'assessed'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software